Evolva completes Abunda acquisition

13-Jul-2011 - Evolva Holding SA announced that it completed the acquisition of Abunda Nutrition, Inc. , after which it will be a wholly-owned subsidiary of Evolva.Evolva’s shareholders approved the capital increase required for the acquisition in the Annual General Meeting (“AGM”) of Evolva on 18 May 2011. As ...

Photocure initiates enrolment into phase II trial of Cevira® for cervical HPV infection

First study to evaluate optimal dose of novel integrated drug-delivery device

21-Jun-2011 - Photocure ASA has initiated patient enrolment in the first trial to evaluate the optimal dose and safety of Cevira, an integrated intravaginal drug-delivery device.The study is a randomized, placebo controlled dose finding study in patients with low to moderate grade cervical intraepithelial ...

Evolva to receive first milestone payment from Roche

15-Jun-2011 - Evolva Holding SA announced that Roche has confirmed that Evolva has achieved its first milestone in their collaboration. Roche will now make a corresponding milestone payment (of an undisclosed amount) to Evolva. The milestone relates to the achievement of diverse, purified active compounds that ...

Q Chip completes US$6 million (£3.6 million) funding round to expand its portfolio of drug formulations and establish a European manufacturing facility

23-May-2011 - Q Chip Limited announced it has completed its US$6 million Series C financing round (the first close was in September 2010).The second close financing was led by Dutch investors Limburg Ventures and Nedermaas Hightech Ventures. They were joined by existing shareholders Disruptive Capital Finance, ...

Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition

20-May-2011 - The Annual General Meeting of Evolva Holding SA has approved all proposals put forward by the Board of Directors, including those regarding the Company’s intended acquisition of its R&D partner Abunda Nutrition, Inc.A total of 85 shareholders were present at the meeting which took place in Basel ...

Photocure: Hexvix/Cysview demonstrates long term benefit

Results from 5.5 year follow up of recurrence of bladder cancer

16-May-2011 - Photocure announced the results from a 5.5 year follow up of recurrence in patients with Non Muscle Invasive Bladder Cancer( NMIBC) showing a long term benefit of the use of Hexvix compared to patients who received white light cystoscopy alone. After a follow-up up period up to 5.5 years, the ...

Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V

Progresses Acromegaly programme towards clinic

13-May-2011 - Syntaxin announced a manufacturing agreement with SynCo Bio Partners B.V. Under the agreement, SynCo will manufacture SXN101959, Syntaxin’s lead internal candidate for Acromegaly, discovered from its Targeted Secretion Inhibitor (TSI) platform. Acromegaly is a chronic and debilitating disease ...

Evolva appoints Norbert Bender as Chief Medical Officer

03-May-2011 - Evolva Holding SA announced that it has appointed Norbert Bender, M.D, Ph.D., an experienced drug development professional, as its Chief Medical Officer (CMO) with immediate effect.Norbert Bender is an M.D. from the University of Frankfurt, Germany and has a Ph.D. in Biochemistry and Pharmacy ...

Photocure Strengthens the Management Team

29-Apr-2011 - Photocure announced the appointment of Kathleen Deardorff, PharmD as Chief Operating Officer from May 1, 2011. In this role, Kathleen will report directly to the President and CEO, Kjetil Hestdal and becomes a member of the Management Team, joining current management team members Christian ...

Evolva proposes two biotech and food ingredient executives to join its Board

26-Apr-2011 - Evolva Holding SA has published the agenda items for the Annual General Meeting, to be held on 18 May 2011 in Basel. The Board term of Ms. Ingelise Saunders expires at this year’s AGM and she is not up for re-election. Evolva’s Board proposes the shareholders to elect Dr. Stuart Strathdee and Dr. ...